Download PDF
Dialyse aktuell 2016; 20(09): 464-465
DOI: 10.1055/s-0042-118436
Forum der Industrie
© Georg Thieme Verlag Stuttgart · New York

Renale Anämie

Optimierung des Anämiemanagements bei CKD-Patienten
Katrin Wolf
Eitorf
› Author Affiliations
Further Information

Publication History

Publication Date:
21 November 2016 (online)

Also available at
   Permissions and Reprints

In der Prä- und Peritonealdialyse sind subkutane Injektionen die Applikation der Wahl, während in der Hämodialyse i. v. ESF (Erythropoese stimulierende Faktoren) im Vordergrund stehen, diskutierten Prof. Johannes Mann vom Kuratorium für Dialyse und Nierentransplantation, München-Schwabing, Prof. Frieder Keller, Universität Ulm, Dr. Eike Wrenger, Eickenhof Dialyse, Langenhagen, Dr. Patrick Biggar vom KfH-Nierenzentrum Coburg und Gabriele Hackenberg, Internistisches Facharztzentrum mit Dialyse in Memmingen, Mindelheim und Leutkirch, im Vorfeld der 8. Jahrestagung der Deutschen Gesellschaft für Nephrologie (DGfN).

 

  • Literatur

  • 1 Macdougall IC, Casadevall N, Locatelli F et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant 2015; 30: 451-460
    CrossrefGoogle Scholar
  • 2 Haag-Weber M, Eckardt KU, Hörl WH et al Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012; 77: 8-17
    CrossrefGoogle Scholar
  • 3 Casadevall N, Dobronravov V, Eckardt KU et al. Evaluation of the safety and immunogenicity of subcutaneous (sc) HX575 epoetin alfa in the treatment of anaemia associated with CKD. Nephrol Dial Transplant 2016; 31 (Suppl. 01) i193-i199
    Google Scholar
  • 4 Collister D, Komenda P, Hiebert B et al. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 472-478
    CrossrefGoogle Scholar
  • 5 René E, Lazrak HH, Laurin LP et al Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case-control study. Nephrol Dial Transplant 21.07.2016 pii: gfw268 [Epub ahead of print]
    Google Scholar
  • 6 Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients. Am J Kidney Dis 12.08.2016; pii: S0272-6386(16)30282-7 DOI: 10.1053/j.ajkd.2016.05.031. [Epub ahead of print]
    Google Scholar
  • 7 Yarnoff BO, Hoerger TJ, Simpson SA et al. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. PLoS One 2016; 11: e0157323
    CrossrefGoogle Scholar
  • 8 Keller F, Ludwig U, Czock D. Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. Expert Opin Drug Metab Toxicol 2015; 11: 139-147
    Google Scholar
  • 9 Improving Global Outcomes (KDIGO) Anemia Work Group. Kidney Int Suppl. 2012; 2: 279-335
    Google Scholar
  • 10 Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience. Clin Nephrol 2011; 75: 59-62
    Google Scholar
  • 11 Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology: Effect of injection frequency on weekly dose. Int J Clin Med 2012; 3: 598-602
    CrossrefGoogle Scholar
  • 12 Coronado Daza J, Martí-Carvajal AJ, Ariza García A et al Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015 12. CD011122
    Google Scholar
  • 13 Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012; 82: 235-241
    CrossrefGoogle Scholar
  • 14 Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J 2015; 36: 657-668
    CrossrefGoogle Scholar
  • 15 Wang AY, Brimble KS, Brunier G et al. ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors. Perit Dial Int 2015; 35: 379-387
    CrossrefGoogle Scholar
  • 16 Pandey R, Daloul R, Coyne DW. Iron Treatment Strategies in Dialysis-Dependent CKD. Semin Nephrol 2016; 36: 105-111
    Google Scholar
  • 17 Snyder JJ, Foley RN, Gilbertson DT et al. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 2004; 15: 174-179
    CrossrefGoogle Scholar
  • 18 Sulowicz W, Locatelli F, Ryckelynck JP et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637-646
    CrossrefGoogle Scholar
  • 19 Wazny LD, Stojimirovic BB, Heidenheim P, Blake PG. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002; 40: 623-628
    CrossrefGoogle Scholar
  • 20 Nicoletta P, Bernardini J, Dacko C et al. Compliance with subcutaneous erythropoietin in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 90-92
    Google Scholar